Clinical Trial Update: A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial evaluating azacitidine or ruxolitinib in combination with selinexor for MDS/MPN overlap syndrome; currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Ruxolitinib (Jakafi) (ruxolitinib)
• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: MDS | Phase 2 | Status: ENROLLING_BY_INVITATION